• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Hyderabad, Feb. 13

EPR Group plans to invest over $500 million to expand its three group companies involved in pharma, gene technologies and cancer research.

EPR Pharma company is expanding its facility at the S.P. Biotech Park Phase-II. The new facility would be ready by the end of this year. It would be used for large scale screening to aid in new drug discovery.

The Group companies are headed by noted scientist Dr E. Prem Kumar Reddy, based in the US. It has its Cancer Research Laboratories located in the Genome Valley, on the outskirts of Hyderabad.

Dr Reddy, who founded Onconova Therapeutics, US, to develop cancer drugs, has transferred some of the methodologies for large scale synthesis of anti-cancer drugs discovered at Onconova to EPR Pharma.

According to a press release, EPR Pharma plans to undertake chemistry-based work and build a portfolio of new chemical entities (NCEs).

EPR Gene Technologies is coming up at the Kolthur biotech park promoted by the Andhra Pradesh Industrial Infrastructure Corporation (APIIC).

The other company EPR Centre for Cancer Research and Bioinformtics, which is also being set up at the APIIC biotech park, would be ready by year end.

More Stories on : New Projects | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Hyundai to supply Accent for Govt

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line